Narcolepsy · Hypersomnolence

Narcolepsy Type 2 and pitolisant: what patients need to know

Written by Dr Ari Manuel, Consultant in Sleep & Respiratory Medicine

Narcolepsy is one of the most underdiagnosed conditions in sleep medicine. The classic presentation of cataplexy — sudden muscle weakness triggered by emotion — is relatively easy to recognise, but Type 2 narcolepsy, which lacks cataplexy, is frequently dismissed or attributed to depression, ADHD, or simply poor sleep habits for years before a correct diagnosis is reached. The journey from first symptom to diagnosis averages over a decade in some studies.

What is Type 2 narcolepsy?

Type 2 narcolepsy is characterised by excessive daytime sleepiness (EDS) and a positive multiple sleep latency test (MSLT), without cataplexy and typically without the low CSF hypocretin levels found in Type 1. The underlying mechanism is less well understood than in Type 1, and the condition can overlap with idiopathic hypersomnia, making precise diagnosis dependent on careful MSLT interpretation in the correct clinical context.

Pitolisant (Wakix) — what it is and how it works

Pitolisant is a histamine H3-receptor antagonist and inverse agonist that enhances histaminergic transmission, promoting wakefulness by a mechanism distinct from traditional stimulants. Crucially, it is not a controlled drug, which makes it practical to prescribe and particularly useful in patients for whom stimulant medications are not appropriate — including those with hypertension, cardiac history, or jobs with driving or safety responsibilities.

NICE Technology Appraisal 677 (2021) recommends pitolisant as an option for treating EDS and cataplexy in adults with narcolepsy. Evidence from the HARMONY trials demonstrates meaningful improvements in daytime sleepiness and cataplexy frequency (Dauvilliers Y et al., Lancet Neurology 2013). It is also used as an adjunctive therapy for residual EDS in patients on established CPAP treatment where objective compliance is good.